CVAC CureVac N.V.

Biotech Analyst Ratings

Latest News

1. 28 April 2022 CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2021 and Provides Business Update

   - Executing on broad vaccine development program, with new clinical studies in COVID-19 and influenza together with GSK to validate advanced second-generation mRNA backbone
   - Initiated Phase 1 dose-escalation study in COVID-19 with CV2CoV, validating mRNA backbone for further variant adaptation
   - Fully recruited Phase 1 dose-escalation study in influenza with differentiated multivalent vaccine candidate, CVSQIV, confirmed good tolerability profile across all doses
   - Bivalent approach for combined Beta/Delta-COVID-19 vaccine candidate shows promising preclinical data, with high neutralizing capacity against each variant, as well as against Omicron
   - Increasing momentum in oncology pipeline by focusing on new avenues for T cell activation as well …

   View Full Article
2. 22 April 2022 CureVac to Report Fourth Quarter and Full-Year 2021 Financial Results and Business Updates on April 28, 2022

   TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 22, 2022 / CureVac N.V. (NASDAQ:CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the fourth quarter and full-year 2021 on Thursday, April 28, 2022. The company will host a conference call and webcast on the same day at 3 p.m. CET / 9 a.m. EST.

   Conference call and webcast details

   Dial-in numbers to participate in the conference call:

   U.S. Toll-Free: +1-877-407-0989
   International: +1-201-389-0921
   Germany: 0800 182 0040

   The live webcast link can be accessed via the newsroom section of the CureVac website at https://www.curevac.com/en/newsroom/events/

   Corresponding…

   View Full Article
3. 21 April 2022 CureVac and GSK's Bivalent Second-Generation mRNA Vaccine Candidate Shown to be Highly Effective Against SARS-CoV-2 Variants in Preclinical Study

   - Vaccine candidate combining Beta- and Delta-specific mRNAs shows strong protection and immune responses during preclinical challenge study

   - Demonstrated neutralizing capacity against the Omicron variant in vaccinated animals

   - Technology adaptation for bivalent approach for COVID-19 vaccines potentially allows for broader protection against emerging variants

   TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 21, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced preclinical data demonstrating immune responses and protective efficacy of a bivalent second-generation COVID-19 vaccine candidate jointly developed…

   View Full Article
4. 11 April 2022 CureVac and GSK Enter into Pandemic Preparedness Contract with German Government

   - German government reserves domestic manufacturing capacity until 2029 to ensure rapid access to mRNA vaccines developed by CureVac and GSK

   - Five-year contract enables production of up to 80 million vaccine doses at short notice in case of a public health emergency, contributing to increased pandemic preparedness

   TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 11, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), and GSK today announced that they have entered into a contract with the German federal government to supply mRNA vaccines within a broader tender for pandemic preparedness in Germany. Following a setup period of…

   View Full Article
5. 30 March 2022 CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV

   • Phase 1 dose-escalation study started at clinical sites in the U.S.
   • Milestone demonstrates CureVac's and GSK's continued execution on comprehensive clinical program of second-generation vaccine candidates for infectious diseases

   TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / March 30, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that the first participant was dosed in a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate, CV2CoV, developed in collaboration with GSK. The clinical trial is expected to provide valuable data to further evaluate the performance of CureVac's second-generation mRNA…

   View Full Article